Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Lek

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
JCI Insight|September 21, 2018
A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathiesPeter R Serafini, Michael J Feyder, Rylie M Hightower, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Deep Mutational Scanning in Disease-related Genes with Saturation Mutagenesis-Reinforced Functional Assays (SMuRF)Kaiyue Ma, Shushu Huang, Kenneth K Ng, et al.
Cell|September 26, 2024
Saturation mutagenesis-reinforced functional assays for disease-related genesKaiyue Ma, Shushu Huang, Kenneth K Ng, et al.
Science Translational Medicine|March 28, 2020
Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophyAngela Lek, Yuanfan Zhang, Keryn G Woodman, et al.
Journal of Neuropathology and Experimental Neurology|March 18, 2011
Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretchLeigh B Waddell, Frances A Lemckert, Xi F Zheng, et al.
The Journal of Clinical Investigation|May 3, 2014
MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptomsMatthew S Alexander, Juan Carlos Casar, Norio Motohashi, et al.
The Journal of Clinical Investigation|October 17, 2023
Profilin1 is required for prevention of mitotic catastrophe in murine and human glomerular diseasesXuefei Tian, Christopher E Pedigo, Ke Li, et al.
The New England Journal of Medicine|September 27, 2023
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular DystrophyAngela Lek, Brenda Wong, Allison Keeler, et al.
Neuromuscular Disorders : NMD|September 26, 2025
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophyJodi M Wolff, Nora Capocci, Evrim Atas, et al.
Nature Genetics|January 10, 2017
SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndromeNatalie D Shaw, Harrison Brand, Zachary A Kupchinsky, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
JCI Insight|September 21, 2018
A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathiesPeter R Serafini, Michael J Feyder, Rylie M Hightower, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Deep Mutational Scanning in Disease-related Genes with Saturation Mutagenesis-Reinforced Functional Assays (SMuRF)Kaiyue Ma, Shushu Huang, Kenneth K Ng, et al.
Cell|September 26, 2024
Saturation mutagenesis-reinforced functional assays for disease-related genesKaiyue Ma, Shushu Huang, Kenneth K Ng, et al.
Science Translational Medicine|March 28, 2020
Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophyAngela Lek, Yuanfan Zhang, Keryn G Woodman, et al.
Journal of Neuropathology and Experimental Neurology|March 18, 2011
Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretchLeigh B Waddell, Frances A Lemckert, Xi F Zheng, et al.
The Journal of Clinical Investigation|May 3, 2014
MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptomsMatthew S Alexander, Juan Carlos Casar, Norio Motohashi, et al.
The Journal of Clinical Investigation|October 17, 2023
Profilin1 is required for prevention of mitotic catastrophe in murine and human glomerular diseasesXuefei Tian, Christopher E Pedigo, Ke Li, et al.
The New England Journal of Medicine|September 27, 2023
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular DystrophyAngela Lek, Brenda Wong, Allison Keeler, et al.
Neuromuscular Disorders : NMD|September 26, 2025
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophyJodi M Wolff, Nora Capocci, Evrim Atas, et al.
Nature Genetics|January 10, 2017
SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndromeNatalie D Shaw, Harrison Brand, Zachary A Kupchinsky, et al.
Pageof 4